Optic neuritis is the most common presenting sign of MS and up to 60% of patients develop permanent visual deficits.
What is the drug?
It’s called ST266 and contains multiple anti-inflammatory cytokines and growth factors.
Intranasal delivery of this drug in mice showed it accumulated at therapeutic levels in optic nerve and in the vitreous and thus reduced visual dysfunction and prevented ganglion cell loss.
The authors state these results suggest intranasal delivery “should be explored as a potentially safer, easier and noninvasive method of delivering existing therapies that could lead to significant changes in current treatment practices”.